Search research articles
Contact Us
Filters
Showing results (101-110 of 108) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 108 results.
Bone Marrow Transplantation
|
May 7, 2024
Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide
Ilias Sinanidis, Michael J Hochman, Hua-Ling Tsai, et al.
Leukemia & Lymphoma
|
March 23, 2021
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)
Michael J Hochman, Megan Othus, Roland B Walter, et al.
Leukemia
|
July 31, 2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
Michael J Hochman, Megan Othus, Robert P Hasserjian, et al.
British Journal of Haematology
|
December 3, 2025
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium
Daniel T Peters, Deedra Nicolet, Yazan F Madanat, et al.
Circulation
|
May 20, 1999
Thrombogenic factors and recurrent coronary events
A J Moss, R E Goldstein, V J Marder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie
|
April 30, 2022
Canadian Surgery Forum
R Fayez, M Roy, S Villeneuve, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 108) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 108 results.
Bone Marrow Transplantation
|
May 7, 2024
Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide
Ilias Sinanidis, Michael J Hochman, Hua-Ling Tsai, et al.
Leukemia & Lymphoma
|
March 23, 2021
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)
Michael J Hochman, Megan Othus, Roland B Walter, et al.
Leukemia
|
July 31, 2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
Michael J Hochman, Megan Othus, Robert P Hasserjian, et al.
British Journal of Haematology
|
December 3, 2025
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium
Daniel T Peters, Deedra Nicolet, Yazan F Madanat, et al.
Circulation
|
May 20, 1999
Thrombogenic factors and recurrent coronary events
A J Moss, R E Goldstein, V J Marder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AML
Joshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.
Haematologica
|
April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
Michael J Hochman, Amy S Ruppert, Ying Huang, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie
|
April 30, 2022
Canadian Surgery Forum
R Fayez, M Roy, S Villeneuve, et al.
Page
of 11